Radioactive 'Smart Bomb' targets cancer in new human trial

NCT ID NCT06305962

Recruiting now Disease control Sponsor: Radiopharm Theranostics, Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or skin cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how it spreads in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-RAD204 (a radioactive antibody that targets PD-L1 on cancer cells)
What this could lead to: If it works, this could lead to a new targeted radiation therapy for several types of advanced solid tumors that have not responded to other treatments.
What could go wrong: This is a very early (Phase 0/1) and small trial with only 30 participants. It is primarily testing safety and dosing, so it is too soon to know if it will be effective. Radioactive treatments can also cause side effects like damage to healthy organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma endometrial cancer endometrium neoplasm head and neck squamous cell carcinoma Lynch syndrome melanoma mismatch repair cancer syndrome 1 non-small cell lung carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS MELANOMA ENDOMETRIAL CANCER HNSCC MMR DEFICIENCY MSI-HIGH NON-SMALL CELL LUNG CANCER PDL1 GENE MUTATION SMALL CELL LUNG CANCER ( SCLC ) TNBC - TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Cancer Research SA (CRSA)
RECRUITING

Adelaide, South Australia, 5000, Australia
GenesisCare Murdoch
RECRUITING

Murdoch, Western Australia, 6150, Australia
Gold Coast University Hospital
RECRUITING

Southport, Queensland, 4215, Australia
Nepean Hospital
RECRUITING

Kingswood, New South Wales, 2747, Australia
Wollongong Hospital
RECRUITING

Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.